Immunosuppressive agents for treating IgA nephropathy-Reference-Cited by-同舟云学术

Immunosuppressive agents for treating IgA nephropathy

Published:2020-03-12 Issue: Volume: Page:
ISSN:1465-1858
Container-title:Cochrane Database of Systematic Reviews
language:en
Short-container-title:

Author:

Natale Patrizia¹²,Palmer Suetonia C³,Ruospo Marinella¹²,Saglimbene Valeria M¹²,Craig Jonathan C⁴⁵,Vecchio Mariacristina⁶,Samuels Joshua A⁷,Molony Donald A⁸,Schena Francesco Paolo¹,Strippoli Giovanni FM¹²⁴

Affiliation:

1. University of Bari; Department of Emergency and Organ Transplantation; Bari Italy

2. The University of Sydney; Sydney School of Public Health; Sydney Australia

3. University of Otago Christchurch; Department of Medicine; 2 Riccarton Ave PO Box 4345 Christchurch New Zealand 8140

4. The Children's Hospital at Westmead; Cochrane Kidney and Transplant, Centre for Kidney Research; Westmead NSW Australia 2145

5. Flinders University; College of Medicine and Public Health; Adelaide SA Australia 5001

6. Danone Research; RD 128 Palaiseau Cedex France 91767

7. UT-Houston Health Science Center; Division of Pediatric Nephrology and Hypertension; 6431 Fannin Street, MSB 3-121 Houston TX USA 77030

8. UT-Houston Health Science Center; Internal Medicine; Division of Renal Diseases and Hypertension 64312 Fannin St Houston TX USA 77030

Publisher

Wiley

Subject

Pharmacology (medical)

Reference229 articles.

1. Reduction of proteinuria observed in response to high dose ACE inhibition and omega-3 fatty acids in pts with IgA nephropathy. Report from the second North American IgA nephropathy trial [abstract no: SA-FC059];Hogg;Journal of the American Society of Nephrology,2007

2. Preliminary report from the second North American IgA nephropathy (IgAN) trial [abstract no: F-PO1098];Hogg;Journal of the American Society of Nephrology,2006

3. Dose-dependency of the effect of omega-3 fatty acids (O3FA) on proteinuria in patients with IgA nephropathy: report from the 2nd North American IgA nephropathy trial [abstract no: F-PO860];Hogg;Journal of the American Society of Nephrology,2005

4. Randomized controlled trial of mycophenolate mofetil in children, adolescents, and adults with IgA nephropathy;Hogg;American Journal of Kidney Diseases,2015

5. Efficacy of omega-3 fatty acids in children and adults with IgA nephropathy is dosage- and size-dependent;Hogg;Clinical Journal of the American Society of Nephrology: CJASN,2006

Cited by 46 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Non-immunosuppressive treatment for IgA nephropathy;Cochrane Database of Systematic Reviews;2024-02-01

2. The role of BAFF and APRIL in IgA nephropathy: pathogenic mechanisms and targeted therapies;Frontiers in Nephrology;2024-02-01

3. The efficacy and safety of hydroxychloroquine versus leflunomide in patients with IgA nephropathy: a single-center experience;Journal of Nephrology;2024-01-16

4. Treatment of IgA Nephropathy: A Rapidly Evolving Field;Journal of the American Society of Nephrology;2023-09-29

5. Urinary N-Acetyl-Beta-D-Glucosaminidase levels predict immunoglobulin a nephropathy remission status;BMC Nephrology;2023-07-14